• Kalliroi-Antonia Passadi 
  • Zoi Fryda 
  • Panagiotis Lepetsos 
  • Christos P. Zafeiris 

##plugins.themes.bootstrap3.article.main##

Tetracyclines have various connections to total joint arthroplasties, including their potential use in perioperative infection prophylaxis, treatment of periprosthetic infections and mitigation of complications such as osteolysis and aseptic loosening. The present study is a narrative review focusing on the potential association of tetracyclines with joint arthroplasties. Tetracyclines have several potential uses in the context of arthroplasties, although they are not commonly used as prophylactic antibiotics during surgery due to concerns about their efficacy against the typical pathogens associated with surgical site infections. However, in the case of prosthetic joint infections, tetracyclines may be considered as part of the antibiotic regimen. After successful treatment of a prosthetic joint infection, some patients may require long-term antibiotic suppression therapy to prevent the recurrence of infection. Tetracyclines, such as doxycycline, may be one option for long-term oral antibiotic therapy in these cases. Minocycline-induced black bone disease and skin pigmentation are adverse events that should be taken into consideration, in terms of joint arthroplasties. The use of doxycycline in the prevention of osteolysis and aseptic loosening is an area of interest and ongoing research in orthopedic surgery, particularly in the context of total joint arthroplasties. Finally, tetracycline labeling in bones can provide valuable insights into implant incorporation and aseptic loosening of prosthetic joints.

Downloads

Download data is not yet available.

Introduction

Tetracyclines represent a class of broad-spectrum antibiotics that have been integral in the treatment of various bacterial infections since their discovery in the mid-20th century. Over the years, their versatility has expanded beyond their initial uses, with applications ranging from common infections to emerging therapeutic avenues. Tetracyclines are characterized by a polycyclic nucleus composed of four fused rings [1]. Common members include tetracycline, doxycycline, minocycline, and demeclocycline. Tetracyclines exhibit bacteriostatic activity by inhibiting bacterial protein synthesis. They achieve this by reversibly binding to the bacterial 30S ribosomal subunit, thereby blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. This interference disrupts the elongation phase of protein synthesis, ultimately halting bacterial growth. Additionally, tetracyclines possess anti-inflammatory, immunomodulatory, and anti-protease properties, contributing to their therapeutic efficacy in non-infectious conditions [2].

Tetracyclines are well-absorbed orally, with variable bioavailability influenced by factors such as food and divalent cations. They distribute widely into tissues and body fluids, including bone and the central nervous system. Metabolism primarily occurs in the liver, with excretion primarily via renal and fecal routes. Different tetracyclines exhibit variations in pharmacokinetic parameters such as absorption, tissue distribution, and elimination half-life. For example, doxycycline demonstrates enhanced bioavailability and tissue penetration compared to tetracycline [3], [4].

Tetracyclines are indicated for a wide range of bacterial infections, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, sexually transmitted infections, and atypical infections such as those caused by Mycoplasma and Chlamydia species. Beyond their antimicrobial properties, tetracyclines have therapeutic utility in non-infectious conditions such as acne vulgaris, rosacea, and periodontal diseases due to their anti-inflammatory and ability to inhibit matrix metalloproteinases. Furthermore, tetracyclines have shown promise in the treatment of various non-infectious conditions, including rheumatoid arthritis, inflammatory bowel disease, and certain dermatological disorders [5]. In recent years, tetracyclines have garnered attention for their potential beyond traditional antimicrobial therapy. Ongoing research explores their role in modulating cellular signaling pathways, inhibiting matrix metalloproteinases involved in tissue remodeling, and combating multidrug-resistant bacterial infections. Furthermore, tetracycline derivatives are being investigated as adjunctive therapies in cancer treatment, neurodegenerative disorders, and periodontal regeneration, highlighting their diverse pharmacological properties and therapeutic potential [6].

Despite their efficacy, tetracyclines are associated with several adverse effects, primarily gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Photosensitivity reactions, tooth discoloration (particularly in children), and hepatotoxicity are also recognized adverse effects. Additionally, tetracyclines may pose risks during pregnancy and childhood due to their affinity for calcium deposition in developing teeth and bones. Rare instances of hepatotoxicity have been reported with tetracycline use, necessitating monitoring of liver function tests during therapy [7]–[9].

Arthroplasty, also known as joint replacement surgery, is a surgical procedure performed to restore function and relieve pain in a diseased or damaged joint by replacing it with an artificial prosthesis. Arthroplasties are commonly performed for degenerative joint conditions such as osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, and avascular necrosis. Total joint arthroplasty involves replacing both the articulating surfaces of the joint with prosthetic components. The artificial components, which are usually made of metal, plastic, or ceramic materials, are implanted to recreate the joint's function and movement. Common examples include total hip replacement and total knee replacement. Partial joint arthroplasty involves replacing only one of the joint surfaces. Examples include unicompartmental knee replacement. Revision arthroplasty is performed to replace a failed or worn-out joint replacement with new prosthetic components [10]–[13].

While arthroplasty is generally safe and effective, complications can occur. These may include infection, venous thromboembolic events, implant loosening or failure, nerve or blood vessel injury, stiffness, instability, and persistent pain. Osteolysis and aseptic loosening are common complications of total joint arthroplasties, particularly in the long term, which can lead to implant failure, revision surgeries, and decreased patient satisfaction [14]. Osteolysis refers to the gradual loss of bone around the prosthetic joint due to a chronic inflammatory response to wear debris, leading to implant instability and eventual loosening. Aseptic loosening occurs when the bond between the implant and bone becomes compromised, resulting in implant migration, pain, and functional impairment [15]. Periprosthetic infections occur when microorganisms colonize the surface of implanted prosthetic joints, leading to infection. These infections can result in substantial morbidity, implant failure, and the need for revision surgery. Surgical options for periprosthetic infections include debridement and implant retention, one- or two-stage revision arthroplasty, resection arthroplasty, or amputation in severe cases [16]. Antimicrobial therapy is a cornerstone of periprosthetic infections management and is typically initiated empirically based on the likely causative organisms, which are often similar to those causing native joint infections. Broad-spectrum antibiotics with activity against Gram-positive cocci, such as Staphylococcus aureus and coagulase-negative staphylococci, are commonly used as initial therapy. Antimicrobial therapy is guided by culture and susceptibility testing of intraoperative specimens obtained during surgical intervention, allowing for targeted therapy tailored to the specific infecting organism and its antimicrobial susceptibility profile [17].

Tetracyclines have various connections to total joint arthroplasties, including their potential use in perioperative infection prophylaxis, treatment of periprosthetic infections and mitigation of complications such as osteolysis and aseptic loosening. The present study is a narrative review focusing on potential association of tetracyclins with joint arthroplasties.

Review

Prophylactic Perioperative Use of Tetracyclines in Joint Arthroplasties

Tetracyclines, including doxycycline and minocycline, are not commonly used as primary perioperative antibiotics in joint arthroplasty procedures. The standard prophylactic antibiotics used in these surgeries typically include agents such as cefazolin or vancomycin, chosen based on factors like the patient's medical history, allergies, and local antimicrobial resistance patterns. This occurs due to the narrower spectrum of activity of tetracyclines compared to antibiotics like cefazolin or vancomycin and the potential development of resistance to tetracyclines [18].

Animal models have shown that a minocycline/rifampin-impregnated bioresorbable polymer implant coating was effective in reducing the rate of prosthetic joint infections, decreasing inflammation and preventing biofilm formation [19]. A prospective randomized controlled trial has observed that preoperative intravenous administration of doxycycline did not significantly decrease Propionibacterium acnes culture positivity of the skin, dermis, or glenohumeral joint of patients undergoing shoulder arthroplasty [20].

Adverse Events of Tetracyclines Affecting Joint Arthroplasties

Minocycline-induced black bone disease is a rare side effect associated with long-term use of the antibiotic minocycline. The condition is characterized by a bluish-gray or black discoloration of bone tissue, particularly in weight-bearing bones such as the tibias, femurs and pelvis. This pigmentation occurs due to the deposition of minocycline metabolites in bone tissue, resulting in an alteration of bone color. Minocycline-induced pigmentation usually occurs after several months to years of continuous therapy with minocycline. The pigmentation is typically irreversible, even after discontinuation of the medication. However, the severity of the pigmentation can vary among individuals. Symptoms of minocycline-induced black bone disease may include bone pain, stiffness, and swelling, although some individuals may not experience any symptoms apart from discoloration [21], [22]. In 2004, McCleskey et al. reported a case of an 81-year-old man who suffered from knee osteoarthritis and was under chronic treatment of rosacea with 100 mg of minocycline daily. During total knee arthroplasty, blue-green to gray pigmentation was noted in the exposed cortical bone of femur and tibia in sites of cartilage erosion [23]. Another similar case of pigmented bone in a 55-year-old woman who was on chronic use of minocycline and sustained a total knee arthroplasty, was reported by Reed et al. in 2012 [22]. Minocycline-induced pigmentation of periarticular bone may be accelerated by inflammation due to rheumatic or pyogenic arthritis [21].

Minocycline-induced skin pigmentation refers to a dermatological side effect associated with the use of minocycline. It typically presents as blue-gray or blue-black discoloration of the skin, mucous membranes, or nails [24]. The pigmentation may develop gradually over time with chronic minocycline use and may be localized or diffuse. The affected areas of the skin may exhibit a slate-gray or bluish hue, which can vary in intensity and distribution [24]. The exact mechanism underlying minocycline-induced skin pigmentation is believed to involve the formation of insoluble minocycline-metal complexes, particularly iron and calcium, within dermal tissues. Minocycline undergoes oxidation in the skin, leading to the formation of pigmented degradation products that deposit in the skin and mucous membranes. The pigmentation is thought to be dose-dependent and may be more likely to occur with prolonged or high-dose minocycline therapy. Minocycline-induced skin pigmentation is usually benign and does not require treatment unless it causes cosmetic concerns or psychological distress. Discontinuation of minocycline therapy may lead to gradual fading or resolution of the pigmentation over time, although complete clearance may not always occur. A periprosthetic knee infection in a 77-year-old man, by methicillin-resistant coagulase-negative staphylococcus, was treated with chronic suppression with oral minocycline and levofloxacin. Skin pigmentation appeared on the patient’s tongue and over the surgical scar of his knee in six months, and later, it extended to his nails, sclera, face, and extremities [24].

Use of Tetracyclines for the Treatment of Arthroplasty-Related Infections

A plethora of clinical studies have supported the efficacy of tetracyclines in the treatment of arthroplasty-related infections. These studies have demonstrated reductions in bacterial load, biofilm formation, and inflammatory response in animal models of PJIs treated with tetracycline-containing regimens. In case a suppressive antibiotic therapy is chosen for the treatment of prosthetic joint infections, doxycycline is the most commonly used antibiotic (61%) [25].

Staphylococci are a common cause of periprosthetic infections. 50% of Staphylococcus aureus biofilm, in case of prosthetic hip and knee infections, can be killed by doxycycline [26]. In 69-year-old man with a methicillin-sensitive Staphylococcus aureus prosthetic hip infection, with a recurrent seroma cavity superficial to fascia lata, injection of 200 mg doxycycline to the cavity, led to a successful seromadesis [27]. The therapeutic combination of minocycline and vancomycin has been used for chronic methicillin-resistant coagulase-negative staphylococcal prosthetic joint infections [28]. Coagulase-negative staphylococci resistance to tetracycline has increased in a little more than a decade [29], [30] and seems to be different between orthopedic centers [31]. Two patients with multidrug-resistant Acinetobacter prosthetic joint infection were reported to be effectively treated by debridement, antibiotics and implant retention. Patients were given high doses of tigecycline followed by standard doses of minocycline for 3 months [32].

Brucella species are bacteria known to cause brucellosis, a zoonotic infection primarily transmitted to humans through direct contact with infected animals or consumption of contaminated animal products such as unpasteurized dairy. While Brucella infections primarily affect organs such as the spleen, liver, and bone marrow, there have been rare cases reported of Brucella causing periprosthetic infections. Two cases of infected total knee arthroplasty by Brucella melitensis were successfully treated with rifampicin and doxycycline without surgery [33], [34]. Cairo et al. reported 3 cases of prosthetic joint infection due to Brucella melitensis, treated with doxycycline in combination with streptomycin or rifampicin [35]. Two other cases of periprosthetic hip infection by Brucella melitensis were managed with a prolonged administration of streptomycin, rifampicin and doxycycline followed by 2-stage revision arthroplasty [36], [37]. Similarly, a periprosthetic hip infection caused by Brucella abortus, was successfully treated with a combination of rifampicin and doxycycline after a 2-stage hip exchange [38]. Walsh et al. reported a case of infected hip arthroplasty by Brucella abortus, 13 years after implantation. Patient was administered intravenous gentamycin, followed by oral doxycycline and rifampicin [39]. Ruiz-Iban et al. reported 2 cases of periprosthetic hip infections caused by Brucella. The first case was caused by Brucella abortus and was managed with a 2-stage exchange and oral administration of rifampicin and doxycycline. The second case was caused by Brucella melitensis and was conservatively managed with rifampicin, streptomycin and doxycycline [40]. Another case of a 78-year-old man with a prosthetic knee infection by Brucella was successfully treated with a 2-stage revision arthroplasty and an oral 8-week administration of rifampicin and doxycycline [41]. Weil et al. suggested that every prosthetic joint infection by Brucella, in the presence of signs of loosening should be treated with a 2-stages excisional arthroplasty and 3 months of administration of doxycycline and rifampicin [42].

Coxiella burnetii is the bacterium responsible for causing Q fever, a zoonotic disease that typically affects animals but can also infect humans. While Coxiella burnetii infections primarily occur through inhalation of contaminated aerosols or ingestion of contaminated food, there have been rare cases reported of Coxiella burnetii causing periprosthetic infections. A periprosthetic knee infection by Coxiella burnetti was successfully treated with one-stage exchange arthroplasty followed by oral administration of doxycycline and moxifloxacin [43]. A case of Coxiella burnetti prosthetic joint infection in an immunocompromised woman was effectively managed with a 2-stage hip exchange and oral doxycyclin and hydroxychloroquine [44]. Another 64-year-old woman with an infected knee arthroplasty by Coxiella burnetti was treated with a 2-stage hip exchange and oral doxycyclin and hydroxychloroquine for 24 months [45]. The combination of doxycycline and ciprofloxacin has been used for the management of another periprosthetic knee infection by Coxiella burnetti [46].

Borellia species are a rare cause of prosthetic joint infections. Ali et al. have reported the successful treatment of Borrelia burgdorferi prosthetic joint infection after total knee arthroplasty with oral doxycycline for 6 weeks [47]. In the case of 2-stage exchange, the combination of intravenous ceftriaxone and oral doxycycline was successful in a patient with Lyme-associated prosthetic joint infection [48]. In a 68-year-old woman with a prosthetic knee infection and a positive serum Lyme antibody testing, the combination of doxycycline and ceftriaxone for 4 weeks led to a successful second-stage implantation [49].

Non-tuberculous mycobacteria are a rare cause of prosthetic joint infections. The combination of doxycycline and moxifloxacin has been used successfully for the management of a periprosthetic knee infection caused by Mycobacterium thermoresistibile [50]. A periprosthetic hip infection by Mycobacterium fortuitum was treated with 4 weeks of intravenous cefoxitin and amikacin and later followed by a 5-month course of oral ciprofloxacin and doxycycline, without any additional surgery [51]. Saffo et al. reported a case of 71-year-old female with a prosthetic knee infection by Mycobacterium smegmatis managed with a 2-stage exchange and a postoperative course of oral doxycycline and levofloxacin [52].

After shoulder arthroplasty, doxycycline has been effective in the treatment of periprosthetic shoulder infection, caused by Propionibacterium acnes [53], [54]. A prosthetic shoulder infection by Propionibacterium granulosum has been successfully treated glenosphere and liner exchange followed by continuous local antibiotic perfusion (gentamycin, ceftriaxone and rifampicin) and oral minocycline and cotrimoxazole for 8 weeks [55].

Doxycycline has been used for the chronic suppression of periprosthetic joint infections caused by rare bacteria, such as Francisella tularensis [56], [57] and Streptococcus gordonii [58]. A patient with an infected knee arthroplasty by Streptobacillus moniliformis was successfully treated with surgical debridement, implant retention, intravenous ceftriaxone for 6 weeks and oral doxycycline for another 6 weeks [59]. A periprosthetic knee infection by Pasteurella multocida was successfully managed with a 2-stage exchange and a course of intravenous amoxicillin, ciprofloxacin and doxycycline [60]. Chronic suppression with minocycline after 6 weeks of vancomycin was reported in a case of prosthetic joint infection by Corynebacterium jeikeium [61]. A 64-year-old man with a history of sarcoidosis on corticosteroids and azathioprine suffered from Nocardia nova knee prosthetic joint infection in the setting of disseminated nocardiosis. He was successfully treated by a one-stage complete hardware exchange followed by an adapted antibiotic therapy regimen (meropenem and doxycycline followed by ceftriaxone and doxycycline) [62]. Luo et al. reported a case of a 59-year-old man with a periprosthetic knee infection by Mycoplasma hominis and Ureaplasma urealyticum, successfully managed with a 3-month course of oral doxycycline [63]. Fourman et al. reported a case of a total hip arthroplasty interrupted by intraoperative cardiac arrest. The patient's wound was packed with sterile sponges and covered with an iodoform dressing. After a successful resuscitation, 6 hours after the incident, the hip arthroplasty was completed. The patient was administered intravenous vancomycin for 2 weeks and oral doxycycline for 12 weeks, with an uneventful healing [64].

Use of Tetracyclines for the Prevention of Aseptic Losening

The use of doxycycline in the prevention of osteolysis and aseptic loosening is an area of interest and ongoing research in orthopedic surgery, particularly in the context of total joint arthroplasties. Doxycycline has been investigated for its potential anti-inflammatory and anti-osteoclastic effects in the context of osteolysis and aseptic loosening [65]. Studies have suggested that doxycycline may inhibit the activity of matrix metalloproteinases, enzymes involved in the degradation of extracellular matrix proteins, including collagen and proteoglycans. By inhibiting matrix metalloproteinases activity, doxycycline may help mitigate the inflammatory response and tissue destruction associated with wear particle-induced osteolysis and aseptic loosening [66].

Preclinical studies using animal models of osteolysis and aseptic loosening have shown promising results with doxycycline treatment, including reductions in bone resorption, inflammatory cytokine levels, and osteoclast activity. A murine osteolysis model suggests that through the downregulation of RANK/RANKL, tetracycline significantly inhibits debris-induced inflammatory osteolysis [67]. In an animal study by Zhang et al. doxycycline treatment effectively suppressed in vitro osteoclastogenesis, affected the fate of mature osteoclasts, and inhibited mature osteoclasts, causing bone resorption. In vivo data suggested that doxycycline strongly attenuates bone cement- or polyethylene-induced osteolysis and osteoclastogenesis. Researchers suggested that doxycycline may be useful in the treatment or prevention of osteolysis and aseptic loosening after joint arthroplasty [65]. An in vitro study by Ong et al. used radiolabelled mouse calvariae cultured with human interface membrane cells from aseptically loosened hips. Researchers found that doxycycline can inhibit osteolysis at the interface membrane of aseptically loosened hips, suggesting a preventive measure for aseptic loosening of total joint replacements [66]. On the other hand, Santavirta et al. observed that doxycycline and tetracycline could inhibit MMP activity in reactive periprosthetic tissue [68].

Use of Tetracyclines for the Prevention of Postoperative Pain, Delirium and Cognitive Dysfunction

A prospective, double-blind, placebo-controlled trial, by Takazawa et al. included 202 patients undergoing total knee arthroplasty under general anesthesia. They were randomly assigned to receive 100 mg of oral minocycline (n = 100) or placebo (n = 102) twice daily from the day before surgery until the seventh postoperative day. Cognitive function was evaluated preoperatively, and 1 week and 3 months postoperatively. Researchers found no significant differences between the 2 groups, in postoperative pain, postoperative delirium and postoperative cognitive dusfunction [69].

Tetracycline Labeling in Bones

Tetracycline labeling in bones refers to a technique used in medical and research settings to study bone formation and turnover. This technique involves the administration of tetracycline antibiotics, followed by examination of bone specimens under a microscope to visualize the deposition of tetracycline within bone tissue. Tetracycline labeling takes advantage of the ability of tetracycline antibiotics to bind to calcium in bone tissue. When tetracycline is administered systemically, it becomes incorporated into the newly formed bone matrix during the process of bone mineralization. By administering tetracycline at specific time intervals and then examining bone specimens, the sequence and rate of bone formation can be tracked and the bone turnover dynamics can be assessed.

Tetracycline antibiotics are typically administered orally or intravenously at predetermined intervals. The timing and duration of tetracycline administration depend on the specific research protocol or clinical question being addressed. Multiple doses of tetracycline may be given over several days or weeks to allow for adequate labeling of bone tissue [70]–[72]. After tetracycline administration, bone specimens are obtained through biopsy or autopsy procedures. Thin sections of bone tissue are prepared and stained using fluorescent dyes or viewed under ultraviolet light to visualize the presence of tetracycline within the bone matrix. Tetracycline labeling appears as fluorescent bands or lines within the bone tissue, corresponding to areas of active mineralization where tetracycline was deposited during bone formation [70]. The spacing and intensity of tetracycline labeling bands provide information about the rate and pattern of bone formation. The intensity of labeling can also indicate the extent of mineralization and the activity of osteoblasts, the cells responsible for bone formation. By comparing tetracycline labeling patterns between different bone specimens or over time, researchers can assess changes in bone metabolism associated with various conditions or interventions [73].

Tetracycline labeling in bones has been used in various clinical and research settings to study bone diseases such as osteoporosis, osteomalacia, and Paget's disease. It has also been utilized to evaluate the effects of osteoporosis medications, such as teriparatide, on bone formation and turnover [71], [74], [75]. Tetracycline labeling can provide valuable insights into implant incorporation and aseptic loosening of prosthetic joints [72], [76], [77].

Tetracycline data has shown that bone viability was not compromised at initial or final reaming levels before hip revision arthroplasty [70]. In femoral head fractures, the apical part of the femoral head has the most extensive vascular damage [78]. The mechanical stability of cemented femoral surface replacement prostheses depends mainly on the original bone present at the time of primary operation [76]. Moreover, it has been shown that 99mTc-Sn-pyrophosphate scintigraphy is an excellent method for the assessment of bone vitality in the femoral head [79]. In the case of the preoperative existence of bone marrow lesions in the femoral heads, increased bone turnover, vascularity and angiogenesis are observed [80]. In bilateral non-cemented total hip arthroplasty, tetracycline labeling indicated active bone turnover in the femoral cortex and regions of ingrowth [71]. Tetracycline treatment showed that in excised femoral heads, new bone tissue contributes to hyperplasia of the osteoarthritic femoral head [73], [75]. New bone formation and ingrowth in bilateral total knee arthroplasty are not inhibited by the administration of celecoxib [81]. However, there are no signs of doxycycline interference with calcium deposition in the trabecular bone from a patient with total hip arthroplasty [82]. Tetracycline labeling has shown that hydroxyapatite-coating showed 90% integration versus 53% of titanium-coated implants [77].

Conclusions

Tetracyclines have several potential uses in the context of arthroplasties, although they are not commonly used as prophylactic antibiotics during surgery due to concerns about their efficacy against the typical pathogens associated with surgical site infections. However, in the case of prosthetic joint infections, tetracyclines may be considered as part of the antibiotic regimen. While tetracyclines are not typically considered first-line agents for prosthetic joint infections, they may be used as alternative agents in cases where the infecting organism is susceptible and other antibiotics are contraindicated or ineffective. After successful treatment of a prosthetic joint infection, some patients may require long-term antibiotic suppression therapy to prevent the recurrence of infection. Tetracyclines, such as doxycycline, may be one option for long-term oral antibiotic therapy in these cases. Minocycline-induced black bone disease and skin pigmentation are adverse events that should be taken into consideration, in terms of joint arthroplasties. The use of doxycycline in the prevention of osteolysis and aseptic loosening is an area of interest and ongoing research in orthopedic surgery, particularly in the context of total joint arthroplasties. Tetracycline labeling in bones can provide valuable insights into implant incorporation and aseptic loosening of prosthetic joints.

References

  1. Jesus K, Moita LF. Tetracyclines: four rings to rule infections through resistance and disease tolerance. J Clin Invest. 2022 Sep 1;132(17):e162331.
     Google Scholar
  2. Pallett AP, Smyth EG. Clinicians’ guide to antibiotics. Tetracycline. Br J Hosp Med. 1988 Nov;40(5):385–90.
     Google Scholar
  3. Warner AJ, Hathaway-Schrader JD, Lubker R, Davies C, Novince CM. Tetracyclines and bone: unclear actions with potentially lasting effects. Bone. 2022 Jun;159:116377.
     Google Scholar
  4. Sjölin-Forsberg G, Hermansson J. Comparative bioavailability of tetracycline and lymecycline. Br J Clin Pharmacol. 1984 Oct;18(4):529–33.
     Google Scholar
  5. Alikhan A, Kurek L, Feldman SR. The role of tetracyclines in rosacea. Am J Clin Dermatol. 2010;11(2):79–87.
     Google Scholar
  6. Singh S, Khanna D, Kalra S. Minocycline and doxycycline: more than antibiotics. Curr Mol Pharmacol. 2021;14(6):1046–65.
     Google Scholar
  7. Dominic MR. Adverse reactions induced by minocycline: a review of literature. Curr Drug Saf. 2021;16(3):309–21.
     Google Scholar
  8. Eljaaly K, Alghamdi H, Almehmadi H, Aljawi F, Hassan A, Thabit AK. Long-term gastrointestinal adverse effects of doxycycline. J Infect Dev Ctries. 2023 Feb 28;17(2):281–5.
     Google Scholar
  9. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol. 1997 Oct;133(10):1224–30.
     Google Scholar
  10. Becker R. Total knee arthroplasty–what do we know and what don’t. Knee Surg Sports Traumatol Arthrosc. 2011 Jul;19(7):1051–2.
     Google Scholar
  11. Cherian JJ, Banerjee S, Kapadia BH, Jauregui JJ, Harwin SF, Mont MA. Cementless total knee arthroplasty: a review. J Knee Surg. 2014 Jun;27(3):193–7.
     Google Scholar
  12. Della Valle CJ. Total knee arthroplasty: what works best? J Knee Surg. 2008 Oct;21(4):259.
     Google Scholar
  13. Newman JM, Sodhi N, Khlopas A, Sultan AA, Chughtai M, Abraham R, et al. Cementless total knee arthroplasty: a comprehensive review of the literature. Orthopedics. 2018 Sep 1;41(5):263–73.
     Google Scholar
  14. Parvizi J, Mui A, Purtill JJ, Sharkey PF, Hozack WJ, Rothman RH. Total joint arthroplasty: when do fatal or near-fatal complications occur? J Bone Joint Surg Am. 2007 Jan;89(1):27–32.
     Google Scholar
  15. Descamps J, Teissier V, Graff W, Mouton A, Bouché PA, Marmor S. Managing early complications in total hip arthroplasty: the safety of immediate revision. J Orthop Traumatol. 2023 Jul 31;24(1):38.
     Google Scholar
  16. Rajput V, Meek RMD, Haddad FS. Periprosthetic joint infection: what next? Bone Joint J. 2022 Nov;104-B(11):1193–5.
     Google Scholar
  17. Gehrke T, Alijanipour P, Parvizi J. The management of an infected total knee arthroplasty. Bone Joint J. 2015;97-B(10 Suppl A):20–9.
     Google Scholar
  18. Spangehl M. Preoperative prophylactic antibiotics in total hip and knee arthroplasty: what, when, and how. J Arthroplasty. 2022 Aug;37(8):1432–4.
     Google Scholar
  19. Bernthal NM, Stavrakis AI, Billi F, Cho JS, Kremen TJ, Simon SI, et al. A mouse model of post-arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant coatings. PLoS One. 2010 Sep 7;5(9):e12580.
     Google Scholar
  20. Rao AJ, Chalmers PN, Cvetanovich GL, O’Brien MC, Newgren JM, Cole BJ, et al. Preoperative doxycycline does not reduce propionibacterium acnes in shoulder arthroplasty. J Bone Joint Surg Am. 2018 Jun 6;100(11):958–64.
     Google Scholar
  21. Yang S, Takakubo Y, Kobayashi S, Asano T, Sasaki A, Sasaki K, et al. Minocycline-induced periarticular black bones in inflamed joints which underwent arthroplastic reconstruction. Clin Orthop Surg. 2012 Sep;4(3):181–7.
     Google Scholar
  22. Reed DN, Gregg FO, Corpe RS. Minocycline-induced black bone disease encountered during total knee arthroplasty. Orthopedics. 2012 May;35(5):e737–9.
     Google Scholar
  23. McCleskey PE, Littleton KH. Minocycline-induced blue-green discoloration of bone. A case report. J Bone Joint Surg Am. 2004 Jan;86(1):146–8.
     Google Scholar
  24. Kobayashi T, Hayakawa K. Minocycline-induced skin pigmentation. Infection. 2017;45(1):129–30.
     Google Scholar
  25. Leijtens B, Weerwag L, Schreurs BW, Kullberg BJ, Rijnen W. Clinical outcome of antibiotic suppressive therapy in patients with a prosthetic joint infection after hip replacement. J Bone Jt Infect. 2019;4(6):268–76.
     Google Scholar
  26. Mandell JB, Orr S, Koch J, Nourie B, Ma D, Bonar DD, et al. Large variations in clinical antibiotic activity against Staphylococcus aureus biofilms of periprosthetic joint infection isolates. J Orthop Res. 2019 Jul;37(7):1604–9.
     Google Scholar
  27. Farrier AJ, Holland J. Seromadesis following total hip resurfacing by aspiration and injection of doxycycline. BMJ Case Rep. 2021 Apr 26;14(4):e241523.
     Google Scholar
  28. Bart G, Zeller V, Kerroumi Y, Heym B, Meyssonnier V, Desplaces N, et al. Minocycline combined with vancomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal prosthetic joint infection managed with exchange arthroplasty. J Bone Jt Infect. 2020;5(3):110–7.
     Google Scholar
  29. Klasan A, Schermuksnies A, Gerber F, Bowman M, FuchsWinkelmann S, Heyse TJ. Development of antibiotic resistance in periprosthetic joint infection after total knee arthroplasty. Bone Joint J. 2021 Jun;103-B(6 Supple A):171–6.
     Google Scholar
  30. Koch JA, Pust TM, Cappellini AJ, Mandell JB, Ma D, Shah NB, et al. Staphylococcus epidermidis biofilms have a high tolerance to antibiotics in periprosthetic joint infection. Life (Basel). 2020 Oct 24;10(11):253.
     Google Scholar
  31. Stevoska S, Himmelbauer F, Stiftinger J, Stadler C, Gotterbarm T, Heyse TJ, et al. Significant difference in antimicrobial resistance of coagulase negative periprosthetic joint infection in septic revision total knee arthroplasty between two major orthopedic centers. J Arthroplasty. 2022 Jun;37(6S):S306–S12.
     Google Scholar
  32. Vila A, Pagella H, Amadio C, Leiva A. Acinetobacter prosthetic joint infection treated with debridement and high-dose tigecycline. Infect Chemother. 2016 Dec;48(4):324–9.
     Google Scholar
  33. Erdogan H, Cakmak G, Erdogan A, Arslan H. Brucella melitensis infection in total knee arthroplasty: a case report. Knee Surg Sports Traumatol Arthrosc. 2010 Jul;18(7):908–10.
     Google Scholar
  34. Tassinari E, Di Motta D, Giardina F, Traina F, De Fine M, Toni A. Brucella infection in total knee arthroplasty. Case report and revision of the literature. Chir Organ Mov. 2008 May;92(1):55–9.
     Google Scholar
  35. Cairó M, Calbo E, Gómez L, Matamala A, Asunción J, Cuchi E, et al. Foreign-body osteoarticular infection by Brucella melitensis: a report of three cases. J Bone Joint Surg Am. 2006 Jan;88(1):202–4.
     Google Scholar
  36. Tena D, Romanillos O, Rodríguez-Zapata M, de la Torre B, PérezPomata MT, Viana R, et al. Prosthetic hip infection due to Brucella melitensis: case report and literature review. Diagn Microbiol Infect Dis. 2007 Aug;58(4):481–5.
     Google Scholar
  37. Ortega-Andreu M, Rodriguez-Merchan EC, Aguera-Gavalda M. Brucellosis as a cause of septic loosening of total hip arthroplasty. J Arthroplasty. 2002;17(3):384–7.
     Google Scholar
  38. Feng JW, Hao P, Hu J, Deng X, Wang Y. Periprosthetic hip infections caused by Brucella: a rare case report and literature review. J Int Med Res. 2024;52(2):3000605241234050.
     Google Scholar
  39. Walsh J, Gilleece A, Fenelon L, Cogley D, Schaffer K. An unusual case of Brucella abortus prosthetic joint infection. J Bone Jt Infect. 2019;4(6):277–9.
     Google Scholar
  40. Ruiz-Iban MA, Crespo P, Diaz-Peletier R, Rozado AM, LopezPardo A. Total hip arthroplasty infected by Brucella: a report of two cases. J Orthop Surg (Hong Kong). 2006;14(1):99–103.
     Google Scholar
  41. Sazegari MA, Bahramian F, Mirzaee F, Zafarani Z, Aslani H. Loosening of total knee arthroplasty after brucellosis infection: a case report. Arch Bone Jt Surg. 2017 Jan;5(1):70–2.
     Google Scholar
  42. Weil Y, Mattan Y, Liebergall M, Rahav G. Brucella prosthetic joint infection: a report of 3 cases and a review of the literature. Clin Infect Dis. 2003 Apr 1;36(7):e81–6.
     Google Scholar
  43. Huang H, Wang J, Liu X, Zhang J, Sun T, Li Z. [Research progress of platelet-rich plasma in treatment of discogenic low back pain]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2023 Mar 15;37(3):377–82.
     Google Scholar
  44. Miailhes P, Conrad A, Sobas C, Laurent F, Lustig S, Ferry T. Coxiella burnetti prosthetic joint infection in an immunocompromised woman: iterative surgeries, prolonged ofloxacin-rifampin treatment and complex reconstruction were needed for the cure. Arthroplasty. 2021 Dec 2;3(1):43.
     Google Scholar
  45. Weisenberg S, Perlada D, Peatman T. Q fever prosthetic joint infection. BMJ Case Rep. 2017 Jul 24;2017:bcr2017220541.
     Google Scholar
  46. Tande AJ, Cunningham SA, Raoult D, Sim FH, Berbari EF, Patel R. A case of Q fever prosthetic joint infection and description of an assay for detection of Coxiella burnetii. J Clin Microbiol. 2013 Jan;51(1):66–9.
     Google Scholar
  47. Ali M, Kamson AO, Hussain N, King SG. Lyme prosthetic joint infection in total knee arthroplasty: a case report. JBJS Case Connect. 2021 Jul 30;11(3):e20.00898.
     Google Scholar
  48. Collins KA, Gotoff JR, Ghanem ES. Lyme disease: a potential source for culture-negative prosthetic joint infection. J Am Acad Orthop Surg Glob Res Rev. 2017 Aug;1(5):e023.
     Google Scholar
  49. Crowe M, Giacobazzi M, Griffin E, Storm S. Borrelia burgdorferiA bacterium worthy of consideration in culture-negative prosthetic joint infection. J Am Acad Orthop Surg Glob Res Rev. 2023 Sep 1;7(9):e23.00068.
     Google Scholar
  50. LaBombardi VJ, Shastry L, Tischler H. Mycobacterium thermoresistibile infection following knee-replacement surgery. J Clin Microbiol. 2005 Oct;43(10):5393–4.
     Google Scholar
  51. Ramanathan M, Ayoade F. A case of Mycobacterium fortuitum prosthetic joint infection successfully treated medically without prosthesis explantation or joint debridement. BMJ Case Rep. 2021 Aug 17;14(8):e243675.
     Google Scholar
  52. Saffo Z, Ognjan A. Mycobacterium smegmatis infection of a prosthetic total knee arthroplasty. IDCases. 2016;5:80–2.
     Google Scholar
  53. Budge MD, Koch JA, Mandell JB, Cappellini AJ, Orr S, Patel S, et al. The in vitro efficacy of doxycycline over vancomycin and penicillin in the elimination of Cutibacterium acnes biofilm. Antimicrob Comb Devices (2019). 2020;STP1630:53–64.
     Google Scholar
  54. Corbisiero MF, Batta N, Kyllo H, Smyth A, Allen L, FrancoParedes C. Clinical spectrum of Cutibacterium acnes infections: the SAPHO syndrome. IDCases. 2023;32:e01784.
     Google Scholar
  55. Mashiko R, Hatta T, Nagashima C. Periprosthetic joint infection
     Google Scholar
  56. following reverse shoulder arthroplasty treated with continuous local antibiotic perfusion: a case report. Cureus. 2023
     Google Scholar
  57. Nov;15(11):e49193.
     Google Scholar
  58. Azua EN, Voss LA. Tularemia in a prosthetic joint infection.
     Google Scholar
  59. Orthopedics. 2020 Jan 1;43(1):e54–6.
     Google Scholar
  60. Rawal H, Patel A, Moran M. Unusual case of prosthetic joint
     Google Scholar
  61. infection caused by Francisella tularensis. BMJ Case Rep. 2017 Oct
     Google Scholar
  62. ;2017:bcr2017221258.
     Google Scholar
  63. Fenelon C, Galbraith JG, Dalton DM, Masterson E. Streptococcus
     Google Scholar
  64. gordonii-a rare cause of prosthetic joint infection in a total hip
     Google Scholar
  65. replacement. J Surg Case Rep. 2017 Jan 16;2017(1):rjw235.
     Google Scholar
  66. Fokkema AT, Kampschreur LM, Pirii LE, Zijlstra WP. Rat bite
     Google Scholar
  67. fever in a total knee arthroplasty: an unusual case of periprosthetic
     Google Scholar
  68. joint infection. Arthroplasty. 2022 Apr 2;4(1):13.
     Google Scholar
  69. Heym B, Jouve F, Lemoal M, Veil-Picard A, Lortat-Jacob A,
     Google Scholar
  70. Nicolas-Chanoine MH. Pasteurella multocida infection of a total
     Google Scholar
  71. knee arthroplasty after a “dog lick”. Knee Surg Sports Traumatol
     Google Scholar
  72. Arthrosc. 2006 Oct;14(10):993–7.
     Google Scholar
  73. Tleyjeh IM, Qutub MO, Bakleh M, Sohail MR, Virk A. Corynebacterium jeikeium prosthetic joint infection: case report and literature
     Google Scholar
  74. review. Scand J Infect Dis. 2005;37(2):151–3.
     Google Scholar
  75. Laurent F, Rodriguez-Villalobos H, Cornu O, Vandercam B,
     Google Scholar
  76. Yombi JC. Nocardia prosthetic knee infection successfully treated
     Google Scholar
  77. by one-stage exchange: case report and review. Acta Clin Belg. 2015
     Google Scholar
  78. Aug;70(4):287–90.
     Google Scholar
  79. Luo J, Wu X, Gang X, Zhang N, Wang F, Rong C. Mycoplasma
     Google Scholar
  80. hominis and Ureaplasma urealyticum infections after knee
     Google Scholar
  81. arthroplasty: a case report. Medicine (Baltimore). 2022 Nov
     Google Scholar
  82. ;101(45):e31202.
     Google Scholar
  83. Fourman MS, Singh N, McMahon PJ. Total hip replacement interrupted by intraoperative arrest with a final component in place: a
     Google Scholar
  84. case report. Arch Bone Jt Surg. 2022 Aug;10(8):729–32.
     Google Scholar
  85. Zhang C, Tang TT, Ren WP, Zhang XL, Dai KR. Inhibiting wear
     Google Scholar
  86. particles-induced osteolysis with doxycycline. Acta Pharmacol Sin.
     Google Scholar
  87. Oct;28(10):1603–10.
     Google Scholar
  88. Ong SM, Taylor GJ. Doxycycline inhibits bone resorption by
     Google Scholar
  89. human interface membrane cells from aseptically loose hip replacements. J Bone Joint Surg Br. 2003;85(3):456–61.
     Google Scholar
  90. Chen D, Zhang X, Guo Y, Shi S, Mao X, Pan X, et al. MMP-9
     Google Scholar
  91. inhibition suppresses wear debris-induced inflammatory osteolysis
     Google Scholar
  92. through downregulation of RANK/RANKL in a murine osteolysis
     Google Scholar
  93. model. Int J Mol Med. 2012 Dec;30(6):1417–23.
     Google Scholar
  94. Santavirta S, Takagi M, Konttinen YT, Sorsa T, Suda A.
     Google Scholar
  95. Inhibitory effect of cephalothin on matrix metalloproteinase activity around loose hip prostheses. Antimicrob Agents Chemother. 1996
     Google Scholar
  96. Jan;40(1):244–6.
     Google Scholar
  97. Takazawa T, Horiuchi T, Orihara M, Nagumo K, Tomioka A,
     Google Scholar
  98. Ideno Y, et al. Prevention of postoperative cognitive dysfunction
     Google Scholar
  99. by minocycline in elderly patients after total knee arthroplasty: a
     Google Scholar
  100. randomized, double-blind, placebo-controlled clinical trial. Anesthesiology. 2023 Feb 1;138(2):172–83.
     Google Scholar
  101. Bloebaum RD, Ferguson RP, Neff CM, Van Gorp C, Woolley DL,
     Google Scholar
  102. Hofmann AA. Bone viability determination in human cancellous
     Google Scholar
  103. bone from patients undergoing revision hip arthroplasty. J Arthroplasty. 2004 Sep;19(6):745–50.
     Google Scholar
  104. Bobyn JD, Glassman AH, Goto H, Krygier JJ, Miller JE, Brooks
     Google Scholar
  105. CE. The effect of stem stiffness on femoral bone resorption after
     Google Scholar
  106. canine porous-coated total hip arthroplasty. Clin Orthop Relat Res.
     Google Scholar
  107. Dec;261:196–213.
     Google Scholar
  108. Matsushita I, Morita Y, Gejo R, Kimura T. Severe bone defects
     Google Scholar
  109. and reduced mineralization caused by massive metallosis after total
     Google Scholar
  110. knee arthroplasty: histopathologic and bone morphometric findings. Mod Rheumatol. 2007;17(6):507–10.
     Google Scholar
  111. Chai BF, Tang XM. Origin of bone hyperplasia in osteoarthritic
     Google Scholar
  112. femoral head. Tetracycline labelling and scanning electron microscopic study. Chin Med J (Engl). 1993 Oct;106(10):728–33.
     Google Scholar
  113. Cosman F, Dempster DW, Nieves JW, Zhou H, Zion M, Roimisher
     Google Scholar
  114. C, et al. Effect of teriparatide on bone formation in the human
     Google Scholar
  115. femoral neck. J Clin Endocrinol Metab. 2016;101(4):1498–505.
     Google Scholar
  116. Rooney AM, Dempster DW, Nieves JW, Zhou H, Bostrom
     Google Scholar
  117. MPG, Cosman F. Effects of teriparatide and loading modality
     Google Scholar
  118. on modeling-based and remodeling-based bone formation in the
     Google Scholar
  119. human femoral neck. Bone. 2022;157:116342.
     Google Scholar
  120. Morberg PH, Johansson CB, Reigstad A, Røkkum M. Vital
     Google Scholar
  121. staining of bone in stable, retrieved femoral surface replacement
     Google Scholar
  122. prostheses: a microscopic study of undecalcified ground sections. J
     Google Scholar
  123. Arthroplasty. 2001 Dec;16(8):1004–9.
     Google Scholar
  124. Pazzaglia UE, Brossa F, Zatti G, Chiesa R, Andrini L. The relevance of hydroxyapatite and spongious titanium coatings in fixation
     Google Scholar
  125. of cementless stems. An experimental comparative study in rat
     Google Scholar
  126. femur employing histological and microangiographic techniques.
     Google Scholar
  127. Arch Orthop Trauma Surg. 1998;117(4–5):279–85.
     Google Scholar
  128. Strömqvist B, Hansson LI, Palmer J, Thorngren KG. Femoral head
     Google Scholar
  129. vitality at reoperation for femoral neck fracture complications. Arch
     Google Scholar
  130. Orthop Trauma Surg (1978). 1984;103(4):235–40.
     Google Scholar
  131. Greiff J. Determination of the vitality of the femoral head
     Google Scholar
  132. with 99mTc-Sn-pyrophosphate scintigraphy. Acta Orthop Scand.
     Google Scholar
  133. ;51(1):109–17.
     Google Scholar
  134. Shabestari M, Vik J, Reseland JE, Eriksen EF. Bone marrow
     Google Scholar
  135. lesions in hip osteoarthritis are characterized by increased bone
     Google Scholar
  136. turnover and enhanced angiogenesis. Osteoarthritis Cartilage. 2016
     Google Scholar
  137. Oct;24(10):1745–52.
     Google Scholar
  138. Hofmann AA, Bloebaum RD, Koller KE, Lahav A. Does celecoxib
     Google Scholar
  139. have an adverse effect on bone remodeling and ingrowth in humans?
     Google Scholar
  140. Clin Orthop Relat Res. 2006 Nov;452:200–4.
     Google Scholar
  141. Van Linthoudt D, François R, Ott H. Contribution to the study
     Google Scholar
  142. of tetracycline bone side-effects. Absence of calcium deposition
     Google Scholar
  143. impairment in the trabecular bone of a patient treated during 3.5
     Google Scholar
  144. years with doxycycline. Z Rheumatol. 1991 May–Jun;50(3):171–4.
     Google Scholar